Exact Sciences and the Mayo Clinic are partnering to conduct a study on the real-world, clinical impact of Cologuard on colorectal cancer screening, according to a press release
Researchers aim to enroll more than 150,000 people in the Voyage study, a nationwide, prospective, observational study with at least 7 years follow-up.
“We applaud efforts to gather evidence on the performance and outcomes of colorectal cancer screening,” Paul Limburg, MD, MPH, AGAF, chief medical officer at Exact Sciences and a gastroenterologist at the Mayo Clinic, said in the press release. “This study will be instrumental in further demonstrating the clinical utility of Cologuard, a highly accurate, non-invasive screening option, in our collective effort to reduce the colorectal cancer burden.”
The study will include patients with average risk for CRC who have a valid order for Cologuard and explore how the non-invasive test has affected CRC screening, incidence and mortality rates.
Disclosures: Limburg is employed by Exact Sciences